Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence

Journal of Urology

Volumn 185, Issue 3, 2011, Pages 848-854

  Lawrentschuk, Nathan ^a   Fernandes, Kimberly ^a   Bell, David ^a   Barkin, Jack ^a   Fleshner, Neil ^a  

^a NONE

Author keywords

goserelin; leuprolide; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLEASON SCORE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 79851508522     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.10.055     Document Type: Article

References (29)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225
2. D. Newling Advanced prostate cancer: immediate or deferred hormone therapy? Eur Urol 39 suppl. 2001 15
3. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516
4. E.M. Messing, J. Manola, and M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781
5. J. Fichtner The management of prostate cancer in patients with a rising prostate-specific antigen level BJU Int 86 2000 181
6. J.M. Fitzpatrick New developments in the pharmacological management of prostate cancer BJU Int 85 suppl. 2000 31
7. K. Lassi, and N.A. Dawson Update on castrate-resistant prostate cancer: 2010 Curr Opin Oncol 22 2010 263
8. G. Attard, A.H. Reid, and R. A'Hern Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 2009 3742
9. D.R. Berthold, G.R. Pond, and F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242
10. E.J. Small, P.F. Schellhammer, and C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089
11. C.F. Heyns, M.P. Simonin, and P. Grosgurin Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer BJU Int 92 2003 226
12. E.Y. Yu, R. Gulati, and D. Telesca Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation J Clin Oncol 28 2010 2668
13. C. Huggins, and C. Hodges The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293
14. A.V. Schally, A. Arimura, and Y. Baba Isolation and properties of the FSH and LH-releasing hormone Biochem Biophys Res Commun 43 1971 393
15. S.L. Chang, J.C. Liao, and R. Shinghal Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis J Urol 182 2009 255
16. P.J. Saylor, and M.R. Smith Metabolic complications of androgen deprivation therapy for prostate cancer J Urol 181 2009 1998
17. W.D. Figg, M.H. Hussain, and J.L. Gulley A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation J Urol 181 2009 1104
18. B. Tombala, and R. Bergesb How good do current LHRH agonists control testosterone? Can this be improved with Eligard? Eur Urol suppl. 2005 30
19. M.F. Sarosdy, P.F. Schellhammer, and R. Johnson Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? Urology 55 2000 391
20. P.F. Schellhammer, R. Sharifi, and N.L. Block Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial Casodex Combination Study Group Urology 50 1997 330
21. M.F. Sarosdy, P.F. Schellhammer, and R. Sharifi Comparison of goserelin and leuprolide in combined androgen blockade therapy Urology 52 1998 82
22. H. Lepor Comparison of single-agent androgen suppression for advanced prostate cancer Rev Urol 7 suppl. 2005 S3
23. J.M. Nabholtz, M.A. Mouret-Reynier, and X. Durando Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer Expert Opin Pharmacother 10 2009 1435
24. H.S. Rugo The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors Ann Oncol 19 2008 16
25. S. Greil, E.A. Robinson, and B. Singal Efficacy over time of LHRH analogs in the treatment of PCaa prospective analysis using serum testosterone to determine dosing intervals Urology 73 2009 631
26. W. Kuber, G. Viehberger, and R. Zeillinger Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer Urol Res 19 1991 19
27. G.W. Chodak Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma Urology 33 1989 42
28. M.G. Oefelein Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment Urology 54 1999 694
29. J. Morote, A. Orsola, and J. Planas Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 2007 1290